The DOI matches its Crossref record; 117 of the 119 references it cites were found in a registry or an index.
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Open accessAbstract
Currently available evidence strongly supports the position that the initiating event in Alzheimer's disease (AD) is related to abnormal processing of beta-amyloid (Abeta) peptide, ultimately leading to formation of Abeta plaques in the brain. This process occurs while individuals are still cognitively normal. Biomarkers of brain beta-amyloidosis are reductions in CSF Abeta(42) and increased amyloid PET tracer retention. After a lag period, which varies from patient to patient, neuronal dysfunction and neurodegeneration become the dominant pathological processes. Biomarkers of neuronal injury and neurodegeneration are increased CSF tau and structural MRI measures of cerebral atrophy. Neurodegeneration is accompanied by synaptic dysfunction, which is indicated by decreased fluorodeoxyglucose uptake on PET. We propose a model that relates disease stage to AD biomarkers in which Abeta biomarkers become abnormal first, before neurodegenerative biomarkers and cognitive symptoms, and neurodegenerative biomarkers become abnormal later, and correlate with clinical symptom severity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies of non-demented elderly cohorts overall report approximately 20–40% are PIB-positive [67, 68, 71–78].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These investigations have established that volumetric decline occurs initially in medial temporal lobe grey matter, following tau protein deposition, and is closely correlated to cognitive decline.”
From White matter microstructural abnormality precedes cortical volumetric decline in Alzheimer’s disease: evidence from data-driven disease progression modelling (2022) · cites this paper as Jack Jr. et al 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the regional level, abnormality is evident in medial temporal lobe areas first (hippocampus and entorhinal cortex), then in lateral temporal lobe areas (mid-temporal gyrus and fusiform gyrus) and finally in frontal lobe areas (Jack Jr. et al 2010, Young et al 2014).”
From White matter microstructural abnormality precedes cortical volumetric decline in Alzheimer’s disease: evidence from data-driven disease progression modelling (2022) · cites this paper as Jack Jr. et al 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“because measures of all biomarkers studied to date have considerable overlap with those found other types of dementia (as well the cognitively normal elderly population), it remains difficult to determine whether or not cognitive impairment is due to AD or another more dominant and concurrent process.”
From Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 (2012) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it is Tau pathology and synapse loss that temporally correlate with cognitive impairment and precede overt neurodegeneration (Jack et al., 2010; Scheff et al., 2006; Spires-Jones and Hyman, 2014”
From Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies (2018) · cites this paper as Jack et al., 2010
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Amyloid accumulation probably starts many years before the onset of symptoms,2,26,27 and initiation of anti-amyloid treatment only after dementia develops may be too late to affect the clinical course of the disease.28”
From Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease (2014) · cites this paper as [26]
The cited source says what the claim attributes to it.
In the citing paper
“Firstly, cognitive decline is more closely correlated to neurodegeneration than tau accumulation (Jack Jr. et al 2010).”
From White matter microstructural abnormality precedes cortical volumetric decline in Alzheimer’s disease: evidence from data-driven disease progression modelling (2022) · cites this paper as Jack Jr. et al 2010
The cited source says what the claim attributes to it.
In the citing paper
“Alzheimer’s disease (AD) is characterized by deposition of hallmark pathological peptides and neurodegeneration that progress across partially overlapping neuroanatomical and temporal axes1,2.”
From Integrated multimodal cell atlas of Alzheimer’s disease (2024) · cites this paper as [2]
In the citing paper
“Autosomal dominant mutations to the MAPT (tau) gene lead to neuronal tangle pathology and frontotemporal dementia but not to amyloid plaques 122,123 , suggesting that tau pathology does not induce Aβ pathology.”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [123]
In the citing paper
“Amyloid plaques appear a decade or two before clinical symptoms of AD, but it is tau pathology and synapse loss that correlate best with cognitive impairment during disease progression (Jack et al., 2010).”
From Microglia in Alzheimer’s disease (2018) · cites this paper as Jack et al., 2010
In the citing paper
“Extensive biomarker and imaging studies indicate that amyloid-β aggregation is the earliest pathological event in Alzheimer’s disease, followed at a later stage by pathological changes of tau aggregation extending beyond the limbic system to the neocortex, which correlates with brain atrophy and cognitive decline2,3.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [2]
In the citing paper
“Their timeline states that in individuals who develop AD, Aβ plaque deposition and reduced CSF Aβ occur first. Next, CSF tau levels rise. These changes manifest years before clinical signs or symptoms develop. Later on hippocampal atrophy appears, followed shortly thereafter by memory decline and eventually dementia. Full progression from Aβ changes to clinical decline takes approximately 10 to 20”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [205]
In the citing paper
“Plaque formation rates also vary over time [217]. After a period of rapid accumulation, plaque deposition gradually slows and by the time symptoms manifest plaque deposition is essentially done [20, 205, 218].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [205]
In the citing paper
“data argue symptoms generally manifest only after plaques stop forming (Figure 5) [205, 216, 217].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [205]
In the citing paper
“As people meeting preclinical AD criteria may remain cognitively stable for many years [205, 214], these trials will take a long time to complete.”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [205]
In the citing paper
“The new AD biological framework and the model of pathologic AD biomarkers from Jack and colleagues 18 conceptualize a progressive sequence of measurable biochemical, neurophysiological, and neuroanatomical alterations that can be detected years before psychometrically and clinically noticeable deterioration in cognition, behavior, and function.”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [18]
In the citing paper
“The neuropathological changes that are quintessential for AD diagnosis—namely, the development of amyloid plaques and tau tangles—are considered to develop years before onset of the cognitive changes that characterize AD dementia [26].”
From Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease (2018) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Self-citationImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Interplay between Cortical Spreading Depolarization and Seizures
Kramer, D. R., Fujii, T., Ohiorhenuan, I. E., & Liu, C. Y. (2017) · Stereotactic and Functional Neurosurgery · doi:10.1159/000452841 · Cited by 3,721
Cited by
Sorted by citations
Items 301–400 of 1,077
Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer’s disease
Lim, Y. Y., Maruff, P. T., Pietrzak, R. H., Ames, D. J., Ellis, K. A., Harrington, K., Lautenschlager, N. T., Szoeke, C. E. I., Martins, R. N., Masters, C. L., et al. (2013) · Brain · doi:10.1093/brain/awt286 · Cited by 219
Mullane, K., & Williams, M. J. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 219
Midlife Blood Pressure, Plasma β-Amyloid, and the Risk for Alzheimer Disease
Shah, N. S., Vidal, J., Masaki, K., Petrovitch, H., Ross, G. W., Tilley, C., Demattos, R. B., Tracy, R. P., White, L. R., & Launer, L. J. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.178962 · Cited by 219
Inflammation, Antiinflammatory Agents, and Alzheimer’s Disease: The Last 22 Years
McGeer, P. L., Rogers, J., & McGeer, E. G. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160488 · Cited by 215
Targeting the Synapse in Alzheimer’s Disease
Jackson, J., Jambrina, E., Li, J., Marston, H., Menzies, F., Phillips, K., & Gilmour, G. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00735 · Cited by 215
Regional brain stiffness changes across the Alzheimer's disease spectrum
Murphy, M. C., Jones, D. T., Jack, C. R., Glaser, K. J., Senjem, M. L., Manduca, A., Felmlee, J. P., Carter, R. E., Ehman, R. L., & Huston, J. (2015) · NeuroImage Clinical · doi:10.1016/j.nicl.2015.12.007 · Cited by 215
Self-citationLu, D., Popuri, K., Ding, G. W., Balachandar, R., & Beg, M. F. (2018) · Medical Image Analysis · doi:10.1016/j.media.2018.02.002 · Cited by 215
Charting brain growth and aging at high spatial precision
Rutherford, S., Fraza, C., Dinga, R., Kia, S. M., Wolfers, T., Zabihi, M., Berthet, P., Worker, A., Verdi, S., Andrews, D., et al. (2022) · eLife · doi:10.7554/elife.72904 · Cited by 214
Weston, P. S. J., Simpson, I. J. A., Ryan, N. S., Ourselin, S., & Fox, N. C. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0132-3 · Cited by 214
Neuropsychological Predictors of Conversion from Mild Cognitive Impairment to Alzheimer's Disease
Gainotti, G., Quaranta, D., Vita, M. G., & Marra, C. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130881 · Cited by 214
Modeling Alzheimer’s disease in transgenic rats
Carmo, S. D., & Cuello, A. C. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-37 · Cited by 214
The Utility of Cerebral Blood Flow as a Biomarker of Preclinical Alzheimer’s Disease
Hays, C. C., Zlatar, Z. Z., & Wierenga, C. E. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0261-z · Cited by 213
Fan, Z., Aman, Y., Ahmed, I., Chetelat, G., Landeau, B., Ray Chaudhuri, K., Brooks, D. J., & Edison, P. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.016 · Cited by 212
Reagh, Z. M., Noche, J. A., Tustison, N. J., Delisle, D., Murray, E. A., & Yassa, M. A. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.039 · Cited by 212
Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play
Jack, C. R. (2012) · Radiology · doi:10.1148/radiol.12110433 · Cited by 211
Self-citationMild Cognitive Impairment: Diagnosis, Longitudinal Course, and Emerging Treatments
Vega, J. N., & NEWHOUSE, P. A. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0490-8 · Cited by 211
Brain-Derived Neurotrophic Factor and Alzheimer’s Disease: Physiopathology and Beyond
Diniz, B. S., & Teixeira, A. L. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-011-8154-x · Cited by 211
Imaging and fluid biomarkers in frontotemporal dementia
Meeter, L. H., Kaat, L. D., Rohrer, J. D., & van Swieten, J. C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.75 · Cited by 210
Modeling disease progression via multi-task learning
Zhou, J., Liu, J., Narayan, V. A., & Ye, J. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.03.073 · Cited by 210
Raj, A., LoCastro, E., Kuceyeski, A. F., Tosun, D., Relkin, N. R., & Weiner, M. W. (2015) · Cell Reports · doi:10.1016/j.celrep.2014.12.034 · Cited by 210
Self-citationAmyloid-β and Tau at the Crossroads of Alzheimer’s Disease
Gallardo, G., & Holtzman, D. M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9358-8_16 · Cited by 212
Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease
Boeve, B. F. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70054-1 · Cited by 211
Chertkow, H. M., Feldman, H., Jacova, C., & Massoud, F. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt198 · Cited by 208
Social participation and risk of developing dementia
Sommerlad, A., Kivimäki, M., Larson, E. B., Röhr, S., Shirai, K., Singh-Manoux, A., & Livingston, G. (2023) · Nature Aging · doi:10.1038/s43587-023-00387-0 · Cited by 207
Neurovascular unit impairment in early Alzheimer's disease measured with magnetic resonance imaging
van de Haar, H. J., Jansen, J. F. A., van Osch, M. J. P., van Buchem, M. A., Muller, M., Wong, S. M., Hofman, P. A. M., Burgmans, S., Verhey, F. R. J., & Backes, W. H. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.06.006 · Cited by 207
Predicting MCI outcome with clinically available MRI and CSF biomarkers
Heister, D. S., Brewer, J. B., Magda, S., Blennow, K., McEvoy, L. K., & Initiative, A. D. N. (2011) · Neurology · doi:10.1212/wnl.0b013e3182343314 · Cited by 206
Parnetti, L., Chipi, E., Salvadori, N., D’Andrea, K., & Eusebi, P. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0459-7 · Cited by 206
Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease
Pereira, J. B., Janelidze, S., Ossenkoppele, R., Kvartsberg, H., Brinkmalm, A., Mattsson, N., Stomrud, E., Smith, R. A., Zetterberg, H., Blennow, K., et al. (2020) · Brain · doi:10.1093/brain/awaa395 · Cited by 208
Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer’s Disease
Edmonds, E. C., Initiative, A. D. N., Delano‐Wood, L., Galasko, D. R., Salmon, D. P., & Bondi, M. W. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150128 · Cited by 205
Moradi, E., Hallikainen, I. T., Hänninen, T., & Tohka, J. (2016) · NeuroImage Clinical · doi:10.1016/j.nicl.2016.12.011 · Cited by 205
Maia, L. F., Kaeser, S. A., Reichwald, J., Hruscha, M., Martus, P., Staufenbiel, M., & Jucker, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006446 · Cited by 204
Functional cognitive disorder: dementia’s blind spot
Ball, H. A., McWhirter, L., Ballard, C., Bhome, R., Blackburn, D. J., Edwards, M. J., Fleming, S. M., Fox, N. C., Howard, R., Huntley, J., et al. (2020) · Brain · doi:10.1093/brain/awaa224 · Cited by 203
Network Dysfunction in Alzheimer's Disease: Refining the Disconnection Hypothesis
Brier, M. R., Thomas, J., & Ances, B. M. (2014) · Brain Connectivity · doi:10.1089/brain.2014.0236 · Cited by 203
Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity
Jack, C. R., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V. J., Vemuri, P., Mielke, M. M., Jones, D. T., Senjem, M. L., Gunter, J. L., et al. (2013) · Neurology · doi:10.1212/01.wnl.0000435556.21319.e4 · Cited by 203
Self-citationKorolev, I. O., Symonds, L. L., Bozoki, A., & Initiative, A. D. N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0138866 · Cited by 203
Kobayashi, Y., Kuhara, T., Oki, M., & Xiao, J. (2019) · Beneficial Microbes · doi:10.3920/bm2018.0170 · Cited by 203
Fleisher, A. S., Chen, K., Liu, X., Ayutyanont, N., Roontiva, A., Thiyyagura, P., Protas, H., Joshi, A. D., Sabbagh, M., Sadowsky, C. H., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.04.017 · Cited by 202
Cho, Y., Seong, J., Jeong, Y., & Shin, S. Y. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.09.085 · Cited by 201
Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques
Li, Y., Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Weiner, M. W., Shaw, L. M. J., Masters, C. L., Fowler, C. J., Trojanowski, J. Q., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000013211 · Cited by 201
Self-citationJack, C. R., Wiste, H. J., Botha, H., Weigand, S. D., Therneau, T. M., Knopman, D. S., Graff-Radford, J., Jones, D. T., Ferman, T. J., Boeve, B. F., et al. (2019) · Brain · doi:10.1093/brain/awz268 · Cited by 200
Self-citationRecent advances in the application of metabolomics to Alzheimer's Disease
Trushina, E. V., & Mielke, M. M. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.06.014 · Cited by 200
Bartrés‐Faz, D., & Arenaza‐Urquijo, E. M. (2011) · Brain Topography · doi:10.1007/s10548-011-0195-9 · Cited by 200
Diogo, V. S., Ferreira, H. A., Prata, D. P., & Initiative, A. D. N. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01047-y · Cited by 200
APOE2 enhances neuroprotection against Alzheimer’s disease through multiple molecular mechanisms
Conejero-Goldberg, C., Gomar, J. J., Bobes-Bascaran, T., Hyde, T. M., Kleinman, J. E., Herman, M. M., Chen, S., Davies, P., & Goldberg, T. E. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.194 · Cited by 199
Raskin, J., Cummings, J. L., Hardy, J., Schuh, K. J., & Dean, R. A. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150701103107 · Cited by 199
Howell, J. C., Watts, K. D., Parker, M. W., Wu, J., Kollhoff, A. L., Wingo, T. S., Dorbin, C. D., Qiu, D., & Hu, W. T. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0315-1 · Cited by 198
Pieruccini‐Faria, F., Black, S. E., Masellis, M., Smith, E. E., Almeida, Q. J., Li, K., Bherer, L., Camicioli, R. M., & Montero‐Odasso, M. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12298 · Cited by 198
Regional Aβ-tau interactions promote onset and acceleration of Alzheimer’s disease tau spreading
Lee, W. J., Brown, J. A., Kim, H. R., Joie, R. L., Cho, H., Lyoo, C. H., Rabinovici, G. D., Seong, J., & Seeley, W. W. (2022) · Neuron · doi:10.1016/j.neuron.2022.03.034 · Cited by 198
Estimating long‐term multivariate progression from short‐term data
Donohue, M. C., Jacqmin‐Gadda, H., Le Goff, M., Thomas, R. G., Raman, R., Gamst, A. C., Beckett, L. A., Jack, C. R., Weiner, M. W., Dartigues, J., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.10.003 · Cited by 197
Self-citationvan Harten, A. C., Visser, P. J., Pijnenburg, Y. A. L., Teunissen, C. E., Blankenstein, M. A., Scheltens, P., & van der Flier, W. M. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.08.004 · Cited by 197
Local MRI analysis approach in the diagnosis of early and prodromal Alzheimer's disease
Chincarini, A., Bosco, P., Calvini, P., Gemme, G., Esposito, M. P., Olivieri, C., Rei, L., SQUARCIA, S., Rodriguez, G., Bellotti, R., et al. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.05.083 · Cited by 197
Reversion From Mild Cognitive Impairment to Normal Cognition
Malek‐Ahmadi, M. H. (2016) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000145 · Cited by 197
Li, H., Hou, X., Liu, H., Yue, C., He, Y., & Zuo, X. (2015) · Human Brain Mapping · doi:10.1002/hbm.22689 · Cited by 196
Longitudinal Change of Biomarkers in Cognitive Decline
Lo, R. Y. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.123 · Cited by 197
Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease
Vemuri, P., Wiste, H. J., Weigand, S. D., Knopman, D. S., Shaw, L. M., Trojanowski, J. Q., Aisen, P. S., Weiner, M., Petersen, R. C., Jack, C. R., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21953 · Cited by 195
Self-citationSingh, S. K., Srivastav, S., Yadav, A. K., Srikrishna, S., & Perry, G. L. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/7361613 · Cited by 196
Regulatory Innovation and Drug Development for Early-Stage Alzheimer's Disease
Kozauer, N., & Katz, R. G. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1302513 · Cited by 195
Marseglia, A., Fratiglioni, L., Kalpouzos, G., Wang, R., Bäckman, L., & Xu, W. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.06.3060 · Cited by 195
Effect of lifestyle activities on alzheimer disease biomarkers and cognition
Vemuri, P., Lesnick, T. G., Przybelski, S. A., Knopman, D. S., Roberts, R. O., Lowe, V. J., Kantarci, K., Senjem, M. L., Gunter, J. L., Boeve, B. F., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23665 · Cited by 193
Self-citationCeramides as Novel Disease Biomarkers
Kurz, J., Parnham, M. J., Geißlinger, G., & Schiffmann, S. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.10.009 · Cited by 193
Provenzano, F. A., Muraskin, J., Tosto, G., Narkhede, A., Wasserman, B. T., Griffith, E. Y., Guzman, V. A., Meier, I. B., Zimmerman, M. E., Brickman, A. M., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1321 · Cited by 192
Vasconcelos, B., Stancu, I.-C., Buist, A., Bird, M., Wang, P., Vanoosthuyse, A., Van Kolen, K., Verheyen, A., Kienlen-Campard, P., Octave, J.-N., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1525-x · Cited by 192
Lewczuk, P., Lelental, N., Spitzer, P., Maler, J. M., & Kornhuber, J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140771 · Cited by 192
Can oral infection be a risk factor for Alzheimer's disease?
Olsen, I., & Singhrao, S. K. (2015) · Journal of Oral Microbiology · doi:10.3402/jom.v7.29143 · Cited by 192
Dissociating Normal Aging from Alzheimer’s Disease: A View from Cognitive Neuroscience
Toepper, M. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161099 · Cited by 191
Boosting power for clinical trials using classifiers based on multiple biomarkers
Kohannim, O., Hua, X., Hibar, D. P., Lee, S., Chou, Y.-Y., Toga, A. W., Jack, C. R., Weiner, M. W., & Thompson, P. M. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.022 · Cited by 190
“For an introduction to SVM - comparing it to simpler methods such as linear discriminant analysis (LDA) - please see our tutorial (Morra et al., 2009b).”
InfluentialSelf-citationBischof, G. N., & Park, D. C. (2015) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000212 · Cited by 189
PET amyloid-beta imaging in preclinical Alzheimer's disease
Vlassenko, A. G., Benzinger, T. L. S., & Morris, J. C. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.11.005 · Cited by 188
Samper‐Gonzàlez, J., Burgos, N., Bottani, S., Fontanella, S., Lu, P., Marcoux, A., Routier, A., Guillon, J., Bacci, M., Wen, J., et al. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2018.08.042 · Cited by 188
Fandos, N., Pérez‐Grijalba, V., Pesini, P., Olmos, S., Bossa, M., Villemagne, V. L., Doecke, J., Fowler, C., Masters, C. L., Sarasa, M., et al. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.07.004 · Cited by 187
The potential of functional MRI as a biomarker in early Alzheimer's disease
Sperling, R. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.009 · Cited by 187
Modeling disease progression via fused sparse group lasso
Zhou, J., Liu, J., Narayan, V. A., & Ye, J. (2012) · ACM SIGKDD Conference on Knowledge Discovery and Data Mining (KDD) · doi:10.1145/2339530.2339702 · Cited by 187
A Sensitive Aβ Oligomer Assay Discriminates Alzheimer's and Aged Control Cerebrospinal Fluid
Savage, M. J., Kalinina, J., Wolfe, A. L., Tugusheva, K., Korn, R., Cash-Mason, T., Maxwell, J. W., Hatcher, N. G., Haugabook, S. J., Wu, G., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1675-13.2014 · Cited by 187
Different patterns of gray matter atrophy in early- and late-onset Alzheimer’s disease
Möller, C., Vrenken, H., Jiskoot, L. C., Versteeg, A., Barkhof, F., Scheltens, P., & van der Flier, W. M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.02.013 · Cited by 187
Martínez‐Nicolás, I., Llorente, T. E., Martínez‐Sánchez, F., & Meilán, J. J. G. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.620251 · Cited by 187
Detection of Aggregation-Competent Tau in Neuron-Derived Extracellular Vesicles
Guix, F. X., Corbett, G. T., Cha, D., Mustapić, M., Liu, W., Mengel, D., Chen, Z., Aïkawa, E., Young‐Pearse, T. L., Kapogiannis, D., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030663 · Cited by 186
Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease
Weintraub, D. A., Dietz, N., Duda, J. E., Wolk, D. A., Doshi, J. J., Xie, S. X., Davatzikos, C. A., Clark, C. M., & Siderowf, A. D. (2011) · Brain · doi:10.1093/brain/awr277 · Cited by 185
Iturria‐Medina, Y., Sotero, R. C., Toussaint, P. J., Evans, A. C., & Initiative, A. T. A. D. N. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003956 · Cited by 185
Activities of Daily Living: Where do They Fit in the Diagnosis of Alzheimer’s disease?
Marshall, G. A., Amariglio, R. E., Sperling, R. A., & Rentz, D. M. (2012) · Neurodegenerative Disease Management · doi:10.2217/nmt.12.55 · Cited by 185
Fujita, S., Mori, S., Onda, K., Hanaoka, S., Nomura, Y., Nakao, T., Yoshikawa, T., Takao, H., Hayashi, N., & Abe, O. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.18153 · Cited by 185
Veitch, D. P., Weiner, M. W., Aisen, P. S., Beckett, L. A., DeCarli, C., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Landau, S. M., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12422 · Cited by 184
Self-citationAβ-independent processes—rethinking preclinical AD
Chételat, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.21 · Cited by 184
Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease
Prestia, A., Caroli, A., van der Flier, W. M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., Teunissen, C. E., Wall, A. E., Carter, S. F., Schöll, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182872830 · Cited by 184
Gordon, B. A., Friedrichsen, K., Brier, M., Blazey, T., Su, Y., Christensen, J., Aldea, P., McConathy, J., Holtzman, D. M., Cairns, N. J., et al. (2016) · Brain · doi:10.1093/brain/aww139 · Cited by 184
Smith, R. G., Hannon, E., De Jager, P. L., Chibnik, L., Lott, S. J., Condliffe, D., Smith, A. R., Haroutunian, V., Troakes, C., Al‐Sarraj, S., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.017 · Cited by 184
Brain injury biomarkers are not dependent on β‐amyloid in normal elderly
Knopman, D. S., Jack, C. R., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23816 · Cited by 183
Self-citationWang, Y., Risacher, S. L., West, J. D., McDonald, B. C., Magee, T., Farlow, M. R., Gao, S., O’Neill, D. P., & Saykin, A. J. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130080 · Cited by 183
Vecchio, F., Miraglia, F., Marra, C., Quaranta, D., Vita, M. G., Bramanti, P., & Rossini, P. M. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132087 · Cited by 182
CSF biomarkers cutoffs: The importance of coincident neuropathological diseases
Toledo, J. B., Brettschneider, J., Grossman, M., Arnold, S. E., Hu, W. T., Xie, S. X., Lee, V. M.-Y., Shaw, L. M., & Trojanowski, J. Q. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0983-7 · Cited by 182
Self-citationFactors affecting Aβ plasma levels and their utility as biomarkers in ADNI
Toledo, J. B., Vanderstichele, H., Figurski, M., Aisen, P. S. S., Petersen, R. C., Weiner, M. W., Jack, C. R., Jagust, W., DeCarli, C. S., Toga, A. W., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0861-8 · Cited by 182
Self-citationDeclining functional connectivity and changing hub locations in Alzheimer’s disease: an EEG study
Engels, M. M. A., Stam, C. J., van der Flier, W. M., Scheltens, P., de Waal, H., & van Straaten, E. C. W. (2015) · BMC Neurology · doi:10.1186/s12883-015-0400-7 · Cited by 181
Development of Positron Emission Tomography β-Amyloid Plaque Imaging Agents
Mathis, C. A., Mason, N. S., Lopresti, B. J., & Klunk, W. E. (2012) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2012.07.001 · Cited by 181
Early-onset Alzheimer's Disease: Nonamnestic Subtypes and Type 2 AD
Mendez, M. F. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.11.009 · Cited by 181
Sturm, V. E., Yokoyama, J. S., Seeley, W. W., Kramer, J. H., Miller, B. L., & Rankin, K. P. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301119110 · Cited by 181
Douaud, G., Menke, R. A. L., Gass, A., Monsch, A. U., Rao, A., Whitcher, B., Zamboni, G., Matthews, P. M., Sollberger, M., & Smith, S. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4437-12.2013 · Cited by 180
Atrophy in the parahippocampal gyrus as an early biomarker of Alzheimer’s disease
Echávarri, C., Aalten, P., Uylings, H. B. M., Jacobs, H. I. L., Visser, P. J., Gronenschild, E. H. B. M., Verhey, F. R. J., & Burgmans, S. (2010) · Brain Structure and Function · doi:10.1007/s00429-010-0283-8 · Cited by 180
Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease
Wagner, M., Wolf, S., Reischies, F. M., Daerr, M., Wolfsgruber, S., Jessen, F., Popp, J., Maier, W., Hüll, M., Frölich, L., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318245f447 · Cited by 179
Zahs, K. R., & Ashe, K. H. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.05.004 · Cited by 179
Detection and treatment of Alzheimer’s disease in its preclinical stage
Rafii, M. S., & Aisen, P. S. S. (2023) · Nature Aging · doi:10.1038/s43587-023-00410-4 · Cited by 179
Self-citationAmyloid‐β immunotherapy for alzheimer disease: Is it now a long shot?
Panza, F., Lozupone, M., Seripa, D., & Imbimbo, B. P. (2019) · Annals of Neurology · doi:10.1002/ana.25410 · Cited by 178
Metadata
- Authors
- Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q.
- Affiliations
- Mayo Clinic (US)
- University of California, Berkeley (US)
- University of Pennsylvania (US)
- University of California San Diego (US)
- University of California, San Francisco (US)
- Corresponding author
- Jack, Clifford R
- ORCID
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 9
- Issue
- 1
- Pages
- 119-128
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC2819840
- OpenAlex
- W2167840686
- Cited by
- 4,806
- References
- 119
- Citations by year
- 2026: 273 · 2025: 317 · 2024: 278 · 2023: 259 · 2022: 308 · 2021: 321 · 2020: 359 · 2019: 303 · 2018: 267 · 2017: 283 · 2016: 265 · 2015: 273 · 2014: 335 · 2013: 337 · 2012: 301
- FWCI
- 127.41
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (AG11378)
- National Institute on Aging
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, amyloid PET, tau protein, brain atrophy, FDG-PET, synaptic dysfunction, neurodegeneration, disease stage, biomarkers, cognitive decline
- MeSH terms
- Aging, Alzheimer Disease, Brain, Cognition Disorders, Humans, Magnetic Resonance Imaging, Models, Neurological, Time Factors, Signal Transduction, Biomarkers, Amyloid beta-Peptides, tau Proteins, Disease Progression, Positron-Emission Tomography, Apolipoprotein E4, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
